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Abstract
Uterine leiomyomas (uterine fibroids) arise from smooth muscle tissue in the majority of women by age 45. It is common for
these clonal tumors to develop from multiple locations within the uterus, leading to a variety of symptoms such as pelvic
pain, abnormal uterine bleeding, and infertility. We performed whole exome sequencing on genomic DNA from five pairs of
leiomyomas and corresponding normal myometrium to determine genetic variations unique to leiomyomas. Whole exome
sequencing revealed that the gene encoding transcription factor MED12 (Mediator complex subunit 12) harbored
heterozygous missense mutations caused by single nucleotide variants in highly conserved codon 44 of exon 2 in two of
five leiomyomas. Sanger re-sequencing of MED12 among these five leiomyomas confirmed the two single nucleotide
variants and detected a 42 base-pair deletion within exon 2 of MED12 in a third leiomyoma. MED12 was sequenced in an
additional 143 leiomyomas and 73 normal myometrial tissues. Overall, MED12 was mutated in 100/148 (67%) of the
genotyped leiomyomas: 79/148 (53%) leiomyomas exhibited heterozygous missense single nucleotide variants, 17/148
(11%) leiomyomas exhibited heterozygous in-frame deletions/insertion-deletions, 2/148 (1%) leiomyomas exhibited intronic
heterozygous single nucleotide variants affecting splicing, and 2/148 (1%) leiomyomas exhibited heterozygous deletions/
insertion-deletions spanning the intron 1-exon 2 boundary which affected the splice acceptor site. Mutations were not
detected in MED12 in normal myometrial tissue. MED12 mutations were equally distributed among karyotypically normal
and abnormal uterine leiomyomas and were identified in leiomyomas from both black and white American women. Our
studies show an association between MED12 mutations and leiomyomas in ethnically and racially diverse American women.
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Introduction
Uterine leiomyomas, better known as fibroid tumors, are
clinically apparent in nearly 25% of women by age 45, and they
cause major morbidity in American women. More than 200,000
surgeries are performed each year to either remove the leiomyo-
matous tumors (myomectomy) or the entire uterus (hysterectomy)
[1,2]. These tumors are responsive to steroid hormones such as
estrogen and progesterone, and they often shrink following
menopause [3]. Approximately half of all leiomyomas are
asymptomatic, while the rest cause pelvic pressure and pain,
menometrorrhagia, anemia, premature labor and infertility. These
symptoms are intensified by the common occurrence of multiple
tumors within a single uterus, often necessitating surgical interven-
tion [4].
Previous genetic analyses of leiomyomas have established that
approximately one half of these tumors have an abnormal
karyotype, while the other half are karyotypically normal. We
recently showed that a subset of karyotypically normal leiomyomas
contained microdeletions and microduplications, but there is still a
large proportion of karyotypically normal leiomyomas that have
no known lesions [5]. In karyotypically abnormal leiomyomas,
cytogenetic aberrations commonly include deletions in 7q, trisomy
of chromosome 12, and various translocations between chromo-
somes 12 and 14 involving the high mobility group AT-hook 2
(HMGA2) gene at 12q15, which encodes a transcriptional regulator
[6,7,8,9]. Cytogenetic abnormalities are likely a reflection of
general genomic instability as is true for other tumors. Mutations
in leiomyomas that cause such genomic instabilities are unknown.
Furthermore, heterozygous germline mutations in fumarate hydratase
(FH) can cause a rare disorder of hereditary leiomyomatosis and
renal cell carcinoma (HLRCC [MIM 150800]) [10,11]. However,
fumarate hydratase does not appear to play an important role in
the non-syndromic forms of uterine leiomyomas [12].
Methods
Patient information
This study was approved by the Institutional Review Board of
the University of Pittsburgh as an exempt study (Pittsburgh, PA;
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IRB# PRO11120169), and informed consent was not obtained.
All leiomyoma and myometrial samples were derived from
specimens that were originally obtained for clinical treatment or
pathology purposes only, and specimens did not contain any
personal identifiers or linkage codes. Samples were collected from
women who were diagnosed with uterine leiomyomas and
underwent medically indicated abdominal hysterectomy. Chro-
mosome analysis was performed using standard G-banding
technique. Whole exome sequencing on the initial five pairs of
samples from five different individuals was performed on
randomly selected, karyotypically normal leiomyomas. Subsequent
DNA sequencing was performed on 143 randomly selected
leiomyomas from our biobank of more than 500 samples. The
histology of all samples was reviewed by a board certified
gynecologic pathologist.
Nucleic acid extraction and preparation
Genomic DNAs from all leiomyomas and corresponding
myometrial samples were extracted from 100 mg of freshly frozen
tissue using the Gentra Puregene Blood Kit (QIAGEN, Valencia,
CA, USA), according to the manufacturer’s protocol. RNA was
extracted from a randomly selected group of leiomyoma samples
which harbored MED12 mutations. Tissue samples stored at
280uC were placed in chilled RNAlaterH-ICE (Invitrogen, Carls-
bad, CA, USA) for at least 16 hrs at 220uC to allow for tissue
thawing under preservative conditions prior to RNA isolation.
TRIzolH Reagent (Invitrogen, Carlsbad, CA, USA) was used to
carry out RNA isolations according to the manufacturer’s protocol.
RNA samples were converted to cDNA using SuperScriptH III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s protocol.
Whole exome capture and DNA sequencing
Ten genomic DNA samples (five leiomyomas and five corre-
sponding myometrial samples) were subjected to in-solution exome
enrichment via the SureSelect Human All Exon Kit v2 (Agilent,
Santa Clara, CA). Following exome capture, the samples were
submitted for single read high-throughput sequencing on the
Genome Analyzer IIx (Illumina Inc., San Diego, CA, USA).
Sequencing data analysis
Exome sequencing raw data files were received in FASTQ
format and converted to FASTA format using default settings for
NextGENe v2.16 software (SoftGenetics, State College, PA, USA).
NextGENe was also used for sequence alignment against reference
human genome assembly GRCh37/hg19. Minimum coverage of
5 sequencing reads per base-pair (bp) was required for variant
calling and variants in less than 20% of the sequencing reads were
considered sequencing artifacts. Nucleotides in exons and within
10 bps of the exon-intron junctions were the focus of further
variant analysis.
Variant filtering
The initial steps of variant filtering for the exome sequencing
data were carried out using NextGENe software; later filtering
steps were performed on exported NextGENe files using the
functions available in a spreadsheet. Each pair of leiomyoma and
corresponding normal myometrial tissue was compared indepen-
dently. Our focus was limited to DNA variants which were present
in the leiomyoma but absent in the corresponding normal
myometrium. Minimum coverage of 20 sequencing reads per bp
was required for this stage of variant filtering. Due to the presence
of common variants in both samples, we required the frequency of
the reference allele in the leiomyoma sample to be at least 25% less
than the frequency of the reference allele in the corresponding
myometrial sample in order for the variant to pass the first filtering
step. Variants outside of the exons and exon-intron junctions
(10 bps flanking each exon) were excluded from further analysis.
The variant lists for each tissue type (leiomyoma/myometrium)
were compared against each other to elucidate variants which
were unique to the leiomyoma. DNA variants present in the Single
Nucleotide Polymorphism database v132 (dbSNP132) were
removed (http://www.ncbi.nlm.nih.gov/projects/SNP/). Synon-
ymous single nucleotide variants (SNVs) were also removed.
Finally, DNA variants were evaluated with protein prediction
tools, PolyPhen-2 and SIFT (http://genetics.bwh.harvard.edu/
pph2/; http://sift.jcvi.org/), to reveal variants which were
predicted to have an impact on protein function. The final variant
lists were compared across samples to identify genes commonly
mutated in multiple leiomyomas as a means to focus further study.
MED12 variant validation
Exome sequence data analysis identified one nucleotide in
codon 44 of exon 2 of MED12 which was uniquely mutated in two
of five leiomyomas. To validate the presence of the SNVs, the five
pairs of leiomyoma and corresponding myometrial samples
underwent Sanger re-sequencing of MED12. Oligonucleotide
primers were designed against MED12 (NCBI Gene ID: 9968;
chrX:70,338,406–70,362,304 [GRCh37/hg19]) using Primer3
(http:/frodo.wi.mit.edu/primer3/). Genomic DNA was amplified
with amfisure PCR Master Mix (GenDEPOT, Barker, TX, USA)
under the following conditions: 94uC for 3 min; 35 cycles of 94uC
for 30 sec, 60uC for 30 sec, 72uC for 30 sec; and 72uC for 2 min.
DNA sequences were evaluated using Sequencher software (Gene
Codes Corp., Ann Arbor, MI, USA). Upon confirmation of the
SNVs in two leiomyomas and identification of a deletion missed by
whole exome sequencing (due to length) in a third leiomyoma, an
additional 143 leiomyomas, 73 of which had corresponding
myometrial samples, were screened for variants in MED12 via
Sanger sequencing, as described above. MED12 variant data was
deposited in the Single Nucleotide Polymorphism database
(dbSNP; http://www.ncbi.nlm.nih.gov/projects/SNP/).
cDNA sequencing
MED12 cDNAs of exon 2 and flanking regions (exons 1 and 3)
in ten randomly selected leiomyomas with MED12 variants were
sequenced to verify that the mutated allele was actively expressed
in each leiomyoma. Oligonucleotide primers were designed using
Primer3. cDNA was amplified with amfisure PCR Master Mix
under the previously specified conditions. PCR products were gel
purified using the QIAGEN Gel Extraction Kit (QIAGEN,
Valencia, CA, USA) prior to Sanger sequencing.
Statistical analysis
A one-tailed Fisher’s exact test was performed to determine
statistical significance of associations between categorical variables,
and a p value,0.05 was considered to be significant.
Results
To search for gene(s) that associate with leiomyomas, we
examined the genomic DNA of leiomyomas and corresponding
myometrial samples from five individuals via whole exome
enrichment and high-throughput DNA sequencing. We analyzed
DNA variants in exons and within 10 base-pairs (bps) of exon-
intron junctions, excluding single nucleotide variants (SNVs) that
populate the Single Nucleotide Polymorphism database v132
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(dbSNP132), as well as those that did not affect the protein
sequence. Among analyzed DNA variants, 24 were predicted to be
damaging at the protein level (Table 1). We hypothesized that
potentially damaging mutations within the same gene would be
present in multiple leiomyomas. MED12 (Mediator complex subunit
12; Xq13.1) was the only gene that presented with damaging
variants in more than one leiomyoma. Two novel heterozygous
single nucleotide variants (SNVs) were identified at the same
position in exon 2 of MED12 (codon 44) in two of the five
leiomyomas (c.130G.A, p.G44S; c.130G.C, p.G44C), but not in
the corresponding myometrial samples. Both SNVs were predicted
to be damaging at the protein level. Sanger re-sequencing
confirmed the presence of the two heterozygous MED12 SNVs
identified by whole exome sequencing and also detected a
heterozygous 42 bp deletion predicted to delete fourteen amino
acids in exon 2, including codon 44 (c.122_164del42;
p.V41_D54del), in a third leiomyoma. The 42 bp deletion was
not identified during exome data analysis due to the size of the
deletion, as the average length of each sequencing read generated
by exome sequencing was 74 bps. Overall, three of the five
leiomyomas (60%) expressed one mutant MED12 allele, and no
variants were detected in MED12 in the matched normal
myometrial samples.
Whole exome sequencing yielded MED12 as a candidate gene
associated with uterine leiomyomas. We then sequenced MED12
in an additional 143 leiomyomas and 73 normal myometrial
samples; the leiomyomas were all derived from different
individuals and the corresponding myometrial samples were taken
from 73 of those individuals. MED12 variants were not detected in
the 73 normal myometrial samples; conversely, one mutant allele
was detected in 97/143 leiomyomas (67.8%; Table 2). We
observed 76 heterozygous missense SNVs, 68 of which occurred
at positions 130 and 131 in codon 44 (68/76; 89.5%) and caused
the following amino acid changes: G44R; G44S, G44C, G44A,
G44D, and G44V (Figure 1). Additionally, two other heterozygous
missense SNVs were detected – c.107T.G; L36R (3/143; 2.1%)
and c.128A.C; Q43P (5/143; 3.5%). One leiomyoma exhibited
two consecutive heterozygous SNVs in codon 44 (c.130G.T and
c.131G.T; G44F). All of the amino acid modifications were
predicted to be damaging by PolyPhen-2 and SIFT. Eighteen
tumors (18/143; 12.6%) exhibited heterozygous in-frame dele-
tions/insertion-deletions, ranging in size from two to fifteen amino
acids. Two of the eighteen deletions/insertion-deletions spanned
the intron 1-exon 2 junction, causing a predicted loss of the splice
acceptor, in addition to other amino acids. Furthermore, one SNV
located near the intron 1-exon 2 junction caused an insertion of
two amino acids between codons 33 and 34 in two leiomyomas.
We therefore observed a total of 100/148 (67.6%) leiomyomas
with MED12 variants, while no variants were detected in MED12
in the normal myometrial samples (p,0.0001). These results
suggest a strong association between somatically acquired variants
in MED12 and leiomyomata.
All of the MED12 variants that we observed in uterine
leiomyomas were heterozygous. Since random X chromosome
inactivation allows either the wild-type or the mutant allele to be
expressed, we examined whether mutated MED12 transcripts were
expressed in leiomyomas harboring MED12 DNA variants [13].
We isolated RNA and generated cDNA from a random selection
of ten leiomyomas known to carry MED12 DNA variants. Sanger
sequencing of cDNAs from these leiomyomas revealed that all of
the transcripts derived solely from the mutant MED12 alleles.
These results are consistent with the interpretation that leiomy-
omatous tumors with MED12 DNA variants express a mutant
form of the MED12 protein.
Karyotype data was available for 134 leiomyomas: 85 (63%)
were karyotypically normal, while 49 (37%) had various
cytogenetic abnormalities (Table S1). The proportions of karyo-
typically normal and abnormal leiomyomas were consistent with
previous studies [14,15]. Fifty-nine of 85 leiomyomas (69%) with a
normal karyotype harbored MED12 variants, while 31/49
Table 1. Whole exome data filtering schema for DNA variants.
Sample ID
Variants in exons and
exon-intron junctionsa
Variants unique to
leiomyomab
Filtered
variantsc Filtered SNVs Filtered dels/indels
Damaging
variantsh
Exonicd Intronice Exonicf Intronicg
L1i 13,654 355 13 9 - 2 2 5
L2 13,477 456 18 14i 1 2 1 5i
L3 13,976 342 18 12i 1 4 1 3i
L4 12,799 387 8 6 - 1 1 2
L5 13,513 373 18 11 2 5 - 9
Genomic DNAs from five pairs of leiomyomas and corresponding myometrial samples underwent whole exome enrichment and sequencing. After sequence alignment,
each pair of leiomyoma and corresponding myometrium was independently analyzed using NextGENe software (represented by each row in the table; SoftGenetics,
State College, PA). The DNA variants in each tissue (leiomyoma/normal myometrium) were compared to reveal mutations which were unique to the leiomyoma. After
filtering against the Single Nucleotide Polymorphism database v132 (dbSNP132; http://www.ncbi.nlm.nih.gov/projects/SNP/) and applying protein prediction software
tools, PolyPhen-2 and SIFT (http://genetics.bwh.harvard.edu/pph2/; http://sift.jcvi.org/), we identified MED12 as the only gene commonly mutated in two or more
leiomyomas. The minimum base coverage threshold was 20 sequencing reads per base-pair for variant filtering.
aAll DNA variants in exons and within 10 base-pairs (bps) of exon-intron junctions in introns.
bDNA variants unique to the leiomyoma in exons and within 10 bps of exon-intron junctions in introns.
cDNA variants unique to the leiomyoma in exons and within 10 bps of exon-intron junctions in introns which were not found in dbSNP132.
dExonic single nucleotide variants (SNVs) unique to the leiomyoma which caused a change in the protein sequence and were not found in dbSNP132.
eSNVs unique to the leiomyoma located in introns within 10 bps of exon-intron junctions which were not found in dbSNP132.
fExonic deletions/insertion-deletions (dels/indels) unique to the leiomyoma which were not found in dbSNP132.
gDels/indels unique to the leiomyoma located in introns within 10 bps of exon-intron junctions which were not found in dbSNP132.
hDNA variants unique to the leiomyoma in exons and within 10 bps of exon-intron junctions in introns which were predicted to be damaging to the protein, not found
in dbSNP132.
iLeiomyomas L2 and L3 harbored missense SNVs in exon 2 of MED12 which were detected by exome sequencing and predicted to be damaging. L1 contained a 42 bp
deletion in exon 2 of MED12 which was undetected by exome sequencing but revealed via Sanger sequencing.
doi:10.1371/journal.pone.0033251.t001
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leiomyomas (63%) with an abnormal karyotype had MED12
variants. These results were not statistically significant (p=0.29).
We also had racial information on 143 leiomyomas. Leiomyomas
under analysis were obtained from 23 black American women and
120 white American women. The frequency of MED12 mutation
was 78% (18/23) in black American women and 66% (79/120) in
white American women, but the association between race and
MED12 status was not statistically significant (p=0.36). The
frequency of MED12 mutation was higher when multiple tumors
were detected in a single uterus (72.5%; 87/120) as opposed to a
single tumor (41%; 9/22) (p,0.01).
Discussion
Uterine leiomyomas are benign smooth muscle tumors that can
emanate from anywhere in the uterus and distort uterine anatomy
and function. Leiomyomas are the leading cause of dysfunctional
uterine bleeding and hysterectomies. The clonal origin of
leiomyomas makes them genetically homogenous. However,
karyotypes between individual leiomyomas differ, and abnormal
karyotypes are identified in approximately 40% of cases [14,15,16].
Rare hereditary leiomyomatosis and renal cell carcinoma syndrome
(HLRCC [MIM 150800]) is caused by heterozygous germline
mutations in the gene encoding fumarate hydratase, but the role(s)
of individual genes in common leiomyomas is not well understood
[10,11]. The presence of MED12 variants in nearly 70% of
leiomyomas suggests that MED12 plays an important role in the
genesis of these tumors in both white and black American women.
MED12, mediator complex subunit 12, encodes one of at least 26
proteins that comprise the Mediator complex. This Mediator
forms a molecular bridge between gene-specific transcription
factors and RNA polymerase II (RNAP II) [17]. The Mediator is
divided into four functional units: the head which binds RNAP II,
the middle, the CDK subcomplex which exhibits histone kinase
activity, and the tail which binds gene-specific enhancers. MED12
is part of the CDK subcomplex along with three other proteins:
Cyclin C, CDK8 (Cyclin-dependent kinase 8), and MED13
(Mediator complex subunit 13). MED12 is necessary for CDK8
Table 2. DNA variants in leiomyomas were confined to exon 2 of MED12.
Variant locationa Variant typeb Nucleotide change Protein change Mutated leiomyomasc
Splice site SNV IVS1-8T.A p.E33_D34insPQ 2 (1.4%/2.0%)
Deletion/Indel IVS1-1_139del41 Splice acceptor loss 1 (0.7%/1.0%)
IVS1-2_141del44insAG Splice acceptor loss 1 (0.7%/1.0%)
Exon 2 SNV c.107T.G p.L36R 3 (2.0%/3.0%)
c.128A.C p.Q43P 5 (3.4%/5.0%)
c.130G.C p.G44R 7 (4.7%/7.0%)
c.130G.A p.G44S 9 (6.1%/9.0%)
c.130G.T p.G44C 8 (5.4%/8.0%)
c.131G.C p.G44A 5 (3.4%/5.0%)
c.131G.A p.G44D 32 (21.6%/32.0%)
c.131G.T p.G44V 9 (6.1%/9.0%)
c.130G.T;c.131G.T p.G44F 1 (0.7%/1.0%)
Deletion/Indel c.103_138del36 p.E35_N46del 1 (0.7%/1.0%)
c.107_111del5insGC p.L36_T37delinsR 1 (0.7%/1.0%)
c.111_155del45 p.A38_S52del 1 (0.7%/1.0%)
c.113_121del9 p.A38_N40del 1 (0.7%/1.0%)
c.117_122del6 p.N40_V41del 1 (0.7%/1.0%)
c.118_132del15 p.N40_G44del 1 (0.7%/1.0%)
c.118_134del17insTA p.N40_F45delinsY 1 (0.7%/1.0%)
c.118_146del29insTT p.N40_P49delinsF 1 (0.7%/1.0%)
c.122_148del27 p.V41_P49del 1 (0.7%/1.0%)
c.122_163del42 p.V41_D54del 1 (0.7%/1.0%)
c.123_152del30 p.K42_V51del 1 (0.7%/1.0%)
c.126_131del6 p.K42_G44delinsN 1 (0.7%/1.0%)
c.126_140del15 p.K42_F45del 1 (0.7%/1.0%)
c.129_137del9 p.Q43_N46delinsH 1 (0.7%/1.0%)
c.129_143del15 p.G44_Q48del 1 (0.7%/1.0%)
c.133_144del12 p.F45_Q48del 1 (0.7%/1.0%)
c.149_163del15 p.A50_D54del 1 (0.7%/1.0%)
aSplice site variants were located in intron 1 within 10 base-pairs of the intron 1-exon 2 junction.
bVariants were classified as a single nucleotide variant (SNV) or a deletion/insertion-deletion (indel).
cThe number of leiomyomas with each specific variant is followed in parentheses by the percentage of the total number of leiomyomas under study (148) and the
percentage of the total number of mutated leiomyomas (100), respectively.
doi:10.1371/journal.pone.0033251.t002
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activation [18]; through this interaction, MED12 indirectly aids in
transcriptional regulation, as CDK8/Cyclin C is capable of
phosphorylating the carboxy-terminal domain (CTD) of RNAPII
leading to subsequent transcription of genes with certain types of
promoters [19]. CDK8 is a colorectal cancer oncogene and likely
plays a role in tumorigenesis [20]. MED12 is also important in
chromatin modification and transcriptional repression, indepen-
dent of its role in CDK8 activation [21]. If the current association
is causative, MED12 is a tumor suppressor gene, leading to
abnormal leiomyomatous growth when mutated.
The variants described here are not germline mutations; rather,
they are solely restricted to the tumor. Since MED12 is located on
the X chromosome, random X chromosome inactivation results in
sole expression of the mutated allele with consequent tumorigenesis.
Interestingly, there was no association between karyotype and
MED12mutation, in our study. Numerous karyotype abnormalities
associate with leiomyomas, and it is likely that such chromosomal
imbalances are a secondary consequence of mutations that derail
normal cell cycle controls. We hypothesize that MED12 variants
deregulate the cell cycle in the normal myometrium, resulting in
abnormal growth and genomic instability.
Germline MED12 mutations are responsible for at least two
forms of X-linked mental retardation: Opitz-Kaveggia syndrome
(FG syndrome [MIM 305450]) and Lujan-Fryns syndrome (MIM
309520). The SNVs implicated in these syndromes are located in
exons 21 and 22, affecting the carboxy-terminus of MED12
(p.R961W and p.N1000S, respectively) [22,23]. These two
syndromes are not associated with tumorigenesis and carrier
females are reported to be ‘‘normal’’. None of the syndromic
mutations were present in the leiomyomas under study. The
concentration of variants within exon 2 of MED12 in a significant
subset of leiomyomas indicates that this region of the protein may
be involved in cell cycle control and tumor repression.
MED12 mutations were recently described in leiomyomas from
a group of Finnish women [24]. In Finnish women, MED12 was
found to be mutated in 70% (159/225) of tumors from a total of 80
individuals. Remarkably and similar to our study, they also found
that all of the variants were located in exon 2, and a high
percentage of the SNVs were localized to codon 44 (110/225;
49%). MED12 variants were not limited to Finnish women, as 14/
28 (50%) leiomyomas from eighteen black/colored South African
women carried MED12 variants [25]. These results are in
agreement with our findings that 78% of black American women
carried MED12 variants. A recent study reported that rearrange-
ments involving the 12q14,15 region, and presumably associated
with disruption of the HMGA2 gene, are not associated with
MED12 mutations [26]. Among our cases, only two leiomyomas
exhibited 12q14,15 rearrangements, and neither of these tumors
harbored MED12 variants. Therefore, our sample size was too
small to support or refute a hypothesis that rearrangements
involving 12q14,15 represent a separate genetic pathway.
Our study on outbred American women, including both white
and black individuals, further extends the association of MED12
variants and leiomyomas in various ethnic and racial groups.
Further studies are needed to determine whether this association is
causative or a reflection of other underlying variants in the
myometrial genome which increase susceptibility to leiomyoma
development.
Supporting Information
Table S1 Karyotype and demographic data for geno-
typed uterine leiomyoma. A single tumor (leiomyoma) was
genotyped from 148 patients. We have provided the karyotype of
the genotyped tumor, size of the genotyped tumor, number of
tumors detected (one/multiple), race, age at treatment, and
MED12 status of the genotyped tumor for each patient, where
available. a Race is denoted by B for black American and W for
white American. b MED12 status is indicated by the specific
mutation detected or WT, which denotes wild-type.
(XLS)
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Figure 1. Variants in codon 44 in exon 2 ofMED12 accounted for 71% of mutations in uterine leiomyomas. This schema depicts the full-
length humanMED12 transcript which contains 45 coding exons (6,531 base-pairs/2,177 amino acids). Exon 2, denoted by the asterisk, is located near
the N terminus and contains 105 base-pairs/35 amino acids. Codon 44, which encodes glycine (boxed G), harbored single nucleotide variants in 71/
100 (71%) mutated leiomyomas. These variants replaced guanines at nucleotide positions 130 and 131. All variants changed the amino acid encoded
by codon 44, and these variants were predicted to be damaging. The percentage of the total number of mutated leiomyomas (100) harboring each
variant is noted in parentheses. a One leiomyoma exhibited two consecutive single nucleotide variants at positions 130 and 131.
doi:10.1371/journal.pone.0033251.g001
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